ZR-CHOP in DLBCL With Specific Gene Abnormality

• Status: Recruiting
• Trial end date: 2026-01-04
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 2, single center clinical trial. to evaluating the efficacy and safety of Zanubrutinib in combination with R-CHOP in newly diagnosed diffuse large B-cell lymphoma with specific gene abnormality.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Fudan University
• Treatments: Zanubrutinib

Criteria

Inclusion Criteria:

1. 18-75 years old;

2. histological confirmed, newly-diagnosed diffuse large B-cell lymphoma with one of the following gene abnormality including MYC translocation, MYD88 mutation, CD79B mutation, NOTCH1 mutation and TP53 mutation;

3. Eastern Cooperative Oncology Group (ECOG) status of 0-1; 4) hospitalized patients and received the whole cycle treatment in Fudan University Shanghai Cancer Center-

4. normal hematological, hepatic and renal function.

5. Life expectancy of more than 3 months;

6. Patients had at least one measurable target lesion;

7. LVEF ≥ 50%

8. signed informed consent forms

Exclusion Criteria:

1. hypersensitivity to immunoglobulin;

2. primary central nerves lymphoma

3. History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix;

4. With contraindication of steroid including uncontrolled diabetes;

5. Serious uncontrolled diseases and intercurrent infection;

6. Pregnant or lactating women;

7. hepatitis B infection with HBV-DNA ≥ 104